Synthesis of Novel Thieno[2,3‐d]pyrimidine–Isoxazole Hybrids: Anticancer Activity and Molecular Docking Studies
ChemistrySelect · 2026-11 · 11 (43)
DOI: 10.1002/slct.75183 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 16.11.2026. Verfasst von Venkatesh Reddycherla und 3 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
A novel series of 14 thieno[2,3‐d]pyrimidine–isoxazole hybrids (5a–5n) was designed and synthesized through a molecular hybridization strategy and evaluated for their anticancer potential. The synthesized compounds were investigated for in vitro cytotoxicity using a cell‐viability assay against A549 and NCI‐H460 human non‐small cell lung cancer cell lines, with HEK‐293 cells used to assess cytotoxicity toward normal cells. Among the synthesized derivatives, 5k exhibited the highest cytotoxic activity, with IC 50 values of 4.93 µM against A549 and 5.97 µM against NCI‐H460, comparable to Erlotinib. Molecular docking studies of selected potent compounds with EGFR (PDB ID: 4HJO) provided preliminary insight into their possible binding interactions. However, the docking results do not confirm EGFR inhibition. Overall, the synthesized thieno[2,3‐d]pyrimidine–isoxazole hybrids, particularly 5k, represent potential anticancer compounds warranting further biological and mechanistic investigation.
Zitieren
APA
Reddycherla, V., Reddy, R. B., Chennakesavulu, K., & Reddy, G. R. (2026). Synthesis of Novel Thieno[2,3‐d]pyrimidine–Isoxazole Hybrids: Anticancer Activity and Molecular Docking Studies. ChemistrySelect, 11(43). https://doi.org/10.1002/slct.75183
Vancouver
Reddycherla V, Reddy RB, Chennakesavulu K, Reddy GR. Synthesis of Novel Thieno[2,3‐d]pyrimidine–Isoxazole Hybrids: Anticancer Activity and Molecular Docking Studies. ChemistrySelect. 2026;11(43). doi:10.1002/slct.75183
BibTeX
@article{Reddycherla2026,
author = {Reddycherla, Venkatesh and Reddy, R. Bhaskar and Chennakesavulu, K. and Reddy, G. Ramanjaneya},
title = {Synthesis of Novel Thieno[2,3‐d]pyrimidine–Isoxazole Hybrids: Anticancer Activity and Molecular Docking Studies},
journal = {ChemistrySelect},
year = {2026},
volume = {11},
number = {43},
doi = {10.1002/slct.75183}
}
EUVIMED